An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes in vitro and depresses the development of pig adipose tissue.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

A mouse monoclonal antibody of the IgG2b subclass was raised against porcine adipocyte plasma membranes. This antibody did not cross-react in immunocytofluorescence with any tested cell-type or tissue other than porcine adipocytes. Complement-mediated cytotoxicity was demonstrated in primary cultures of porcine stromal-vascular cells. When the antibody and complement were added to already differentiated cultures, the treatment resulted in elimination of lipid-filled preadipocytes, whereas an early treatment of cultures prevented the appearance of these cells. In vivo, injection of newborn pigs with 1 mg/kg of monoclonal antibody on d 2 and 5 of life produced a more than 20% reduction of subcutaneous and leaf fat lipids at 35 d of age, whereas the lipid content of the longissimus muscle remained unaffected. These results demonstrate that early systemic treatment of pigs with a specific anti-adipocyte antibody reduces the fat mass. In addition to their potential in vivo use, monoclonal antibodies directed against adipose determinants may be useful tools for studying adipocyte lineage.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.